Six months multicentre pilot open label single‐arm study to evaluate patient experience, acceptability and satisfaction of switching certolizumab pegol from a prefilled syringe or autoinjection pen to an AVA ® e‐Device in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis patients | Publicación